Nrf2 Activation Compositions, Treat Inflammation, Oxidative Stress
Summary
USPTO published patent application US20260108575A1 on April 23, 2026, filed by Brooks Michael Hybertson and Joe Milton McCord under Application No. 19370063. The application covers compositions containing phytochemicals that activate Nrf2 pathways for preventing or treating health conditions associated with inflammation or oxidative stress. The filing date was October 27, 2025, and CPC classifications include A61K 36/53, A61K 31/352, A61K 36/906, and A61K 45/06.
“Disclosed here are compositions and methods for preventing or treating certain health conditions associated with inflammation or oxidative stress.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108575A1 on April 23, 2026, disclosing compositions and methods for treating inflammation and oxidative stress through Nrf2 pathway activation using phytochemicals. The application names Brooks Michael Hybertson and Joe Milton McCord as inventors and lists A61K classifications covering herbal and phytochemical preparations.
Affected parties include pharmaceutical and supplement manufacturers developing anti-inflammatory or antioxidant therapies. This publication signals potential future competition in the Nrf2-activation therapeutic space and establishes a priority date of October 27, 2025 for the disclosed inventions.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS FOR IMPROVED NRF2 ACTIVATION AND METHODS OF THEIR USE
Application US20260108575A1 Kind: A1 Apr 23, 2026
Inventors
Brooks Michael Hybertson, Joe Milton McCord
Abstract
Disclosed here are compositions and methods for preventing or treating certain health conditions associated with inflammation or oxidative stress. These compositions are prepared from ingredients containing phytochemicals that activate the Nrf2 pathways. Synergistic effects of the different phytochemicals are also disclosed.
CPC Classifications
A61K 36/53 A61K 31/352 A61K 36/906 A61K 45/06
Filing Date
2025-10-27
Application No.
19370063
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.